BIONTECH SE ADR
Action · US09075V1026 · BNTX · A2PSR2 (XFRA)
95,25 EUR
Cours de clôture XFRA 06.06.2025:
96,45 EUR
Frankfurt (XNAS) · Cours et graphiques actuels sur MoneyPeak
06.06.2025 22:29
Cours actuels de BIONTECH SE ADR
Bourse | Ticker | Devise | Dernier échange | Cours | Variation journalière |
---|---|---|---|---|---|
![]() NASDAQ |
BNTX
|
USD
|
06.06.2025 22:29
|
108,54 USD
| 110,15 USD
-1,46 %
|
![]() Frankfurt |
22UA.F
|
EUR
|
06.06.2025 17:13
|
96,45 EUR
| 97,75 EUR
-1,33 %
|
Performance
Jour | Semaine | Mois | 3 mois | 6 mois | 1 an | 5 ans |
---|---|---|---|---|---|---|
0,00 % | 12,96 % | 13,69 % | -6,90 % | -17,32 % | 1,06 % | 118,66 % |
Profil de l'entreprise pour BIONTECH SE ADR Action
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
Fonds investis
Les fonds suivants ont investi dans : BIONTECH SE ADR investi :
Fonds | Vol. en millions 862,43 | Part (%) 2,02 % |
Données de l'entreprise
Nom BIONTECH SE ADR
Société BioNTech SE
Symbole BNTX
Site web
https://www.biontech.de
Marché d'origine
Frankfurt

WKN A2PSR2
ISIN US09075V1026
Type de titre Action
Secteur Healthcare
Industrie Biotechnology
PDG Dr. Ugur Sahin M.D.
Capitalisation boursière 21 Mrd.
Pays Allemagne
Devise EUR
Employés 6,8 T
Adresse An der Goldgrube 12, 55131 Mainz
Date d'introduction en bourse 2019-10-11
Symboles boursiers
Nom | Symbole |
---|---|
Frankfurt | 22UA.F |
NASDAQ | BNTX |
XETRA | 22UA.DE |
Autres actions
Les investisseurs qui détiennent BIONTECH SE ADR ont également les actions suivantes dans leur portefeuille :
La plateforme financière MoneyPeak suit et analyse les investissements et les portefeuilles.
Du dépôt de titres à l'achat de crypto.
Utile, simple et gratuit. Actions, ETF, ETC, ETN, indices, fonds, obligations, certificats, devises, options, droits de souscription.
Utile, simple et gratuit. Actions, ETF, ETC, ETN, indices, fonds, obligations, certificats, devises, options, droits de souscription.